IMPROVING PATIENT OUTCOMES IN ORPHAN DISEASES

Lobe Sciences is a Biotech company focused on the research and development of innovative medicines we discovered. Our focus gives us the opportunity to improve the outcomes of patients of all ages afflicted with disorders where there are currently poor or no effective treatments.

Developing and delivering solutions to improve the human condition.

Our mission is to discover and develop proprietary compounds to advance into clinical trials for Orphan Diseases.  We believe that our drugs ability to “rewire” or “reset” the brain will result in the improvement of symptoms associated with numerous diseases.

Our goal is to commercialize our drugs for the treatment of Orphan Diseases.

Our Science Explained

Targeting the 5-HT2A receptor which is a G-protein-coupled receptor, commonly found in serotonin-rich areas of the brain, which are thought to manifest psychedelics’ effects (Kyzar et al., 2017).

Activation of this receptor results in the increased expression of key genes involved in creating new synapses in the brain (Nichols & Sanders-Bush, 2002).

This could influence the plasticity of neurons after a single dosage, establishing new long-term connections.

This brain “reset” or rewiring could be caused by the growth of dendritic spines on neurons—which represent new neural connections.

These long-lasting changes in neural architecture could underlie psilocybin’s brain “reset” which is likely essential for treating various mental health conditions.

The Team

team member

Philip J. Young

CEO & DIRECTOR

BIO

X

Philip J. Young

CEO & DIRECTOR

Mr. Young is an analytical and results driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a Director and Chief Executive Officer for public companies for the past 20 years where has had created significant shareholder value, built integrated scientific, manufacturing and commercial operations, directed successful M&A transactions and was responsible for generating more the $900M through acquisitions and equity financings. Mr. Young started his management career in the biopharmaceutical industry at Genentech Inc. where he was responsible for their cardiovascular and endocrine product launches sales and marketing.

team member

Mathew Lee

CHIEF FINANCIAL OFFICER

BIO

X

Mathew Lee

CHIEF FINANCIAL OFFICER

Mathew has over 15 years of experience as a finance executive. Mathew currently serves as president of Manning Lee Management Ltd., a management consulting firm providing CFO services to publicly traded companies. Mathew specializes in providing M&A, accounting, management, securities regulatory compliance, and corporate secretarial services to companies listed on the TSX-V, CSE, and OTC. Mathew is a CPA Charterholder and earned a B.Comm from the University of British Columbia.

team member

Frederick D. Sancilio, Ms, PhD.

Regulatory, CMC, Clinical Development

BIO

X

Frederick D. Sancilio, Ms, PhD.

Regulatory, CMC, Clinical Development

Dr. Sancilio is a serial entrepreneur in the healthcare field and is currently a
principle of Clearway Global, Inc., a pharmaceutical development advisory service.
He has served as an executive and director of both private and public companies,
including Applied Analytical Industries, Inc., aaiPharma, Inc., Endeavor
Pharmaceutical Company, Aesgen, Inc., Sancilio & Company, Alpha Cognition, Inc.,
TrippBio, Inc., Omega Blu, LLC, and Nation’s Bank of North Carolina. He was
appointed as a Research Professor at Florida Atlantic University and was an adjunct
professor of chemistry at the University of North Carolina. Dr. Sancilio received his
Master of Science and Doctorate degrees from Rutgers, The State University of
New Jersey.

team member

Baxter Phillips III

COO & Director

BIO

X

Baxter Phillips III

COO & Director

Baxter is a seasoned life sciences executive whose experience
spans the continuum from preclinical drug research and
manufacturing to product launch, commercialization and
operations management and finance. In his 20+ years in the
pharmaceutical industry he has served as a director and C-Level
executive and director of multiple public and private companies,
including Insmed (INSM), Asertio (ASRT), and Neurogastrx. He has
a B.S. in Biology from Hampden-Sydney College and an MBA from
The Mason School of Business at the College of William and
Mary.

team member

Maghsoud Dariani

CHIEF SCIENCE OFFICER

BIO

X

Maghsoud Dariani

CHIEF SCIENCE OFFICER

Prior to leading science and technology efforts at LOBE, Dariani was President of Focus Pharmaceuticals, Inc., where he managed the development and approval of drug products, achieving one FDA approval and bringing another to the clinical evaluation stage, then successfully negotiated the sale of the company in February 2003. Prior to Focus, Maghsoud was Vice President of the chiral pharmaceutical business unit at Celgene Corporation. During his twelve years at Celgene, he was responsible for the successful development and FDA approval of the chirally pure versions of Ritalin, which are currently marketed by Novartis under the Focalin and Focalin XR trade names.

team member

Michael Petter

DIRECTOR

BIO

X

Michael Petter

DIRECTOR

Michael is an accomplished leader and entrepreneur in the psychedelics and cannabis industry, co-founding and acting as a director of several companies that successfully completed M&A transactions. He holds a Bachelors in Computer Science from London University, is a Chartered Engineer and private pilot. Since January 2009, he has been the Managing Director of Eyvo eProcurement Solutions, a US-based private company that is a leading eProcurement provider in the SaaS space. He also runs a business mentoring program that assists businesses and individuals with change management. Mike was co-founder and director of Eleusian Biosciences Corp., which the Company acquired in July 2020. He also co-founded and was a director of Tassili Life Sciences Corp. which was acquired by CSE-listed Champignon Brands Inc. in March 2020. Mr. Petter has independent board experience being chairman of a compensation committee and as a member of an audit committee. His executive advisory skills focus on providing guidance on strategy, operations, finance and logistics.

team member

Ilan Hayman

ADVISOR

BIO

X

Ilan Hayman

ADVISOR

Ilan has played a pivotal role in the General Management of healthcare businesses including a private cosmetic surgery chain and the commercialisation of a breakthrough skincare range. He successfully led the development of these products from concept through to production commercialisation. Most recently Ilan oversaw a group of national medical centers. His career into operations management was triggered by his valuable experience as part of the Risk and Controls Solutions practice at PricewaterhouseCoopers (PwC). Specifically, Ilan’s passion is assisting the medical fraternity in their practice management and business administration functions. Ilan’s ambition is to work in a role that utilises his analysis expertise enriched by his exposure to the commercial side of business. Ilan has a passion for assisting community organisations and sits on several boards of not for profit organisations. He also holds Bronze and Silver Duke of Edinburgh awards and brings along a unique set of community and industry related experience.

team member

Bart Oates

ADVISOR

BIO

X

Bart Oates

ADVISOR

Bart Oates Esq. is a three-time Superbowl Champion, who graduated magna cum laude with a Juris Doctor degree from Seton Hall during his off season. Prior to his NFL career, he earned a BS in Accounting from the Marriott School of Business at BYU and was inducted into their athletic Hall of Fame in 1992. Bart was selected to five Pro Bowls during his NFL career and to the UPI All-NFC team three times. Bart is now the President of the NFL Alumni Association which offers former players a diverse package of medical, business, and legal services to help keep them and their families healthy, productive, and connected to their former teammates.

team member

Gilberto Jesús Mendoza

ADVISOR

BIO

X

Gilberto Jesús Mendoza

ADVISOR

Gilberto Jesús Mendoza is currently the President of the World Boxing Association. Mr. Mendoza began his career as a lawyer and an engineer and has been working with the WBA since 2015. His priority has always been to give opportunities to the most vulnerable regions of the world. He has spent time in close contact with athletes since he was a child and has actively participated in the intention to rescue amateur boxing. Mr. Mendoza is the proud creator of “Un Solo Boxeo” (Only One Boxing), a program that promotes the integration of professional boxing. He also created the Future WBA Champion, a project that has given space to thousands of boxers in their preparation stage for the Tokyo Olympic Games. Mr. Mendoza’s goal is the growth and development of boxing, as well as its adaptation to change.